A study to describe and evaluate the spontaneous adverse event reports of alopecia attributed to erenumab in the FDA adverse events reporting system (FAERS)
Latest Information Update: 10 Dec 2020
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine
- Focus Adverse reactions
- 10 Dec 2020 New trial record